Recombinant Anti-BTBD17 antibody [EPR9593(B)] (ab138507)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR9593(B)] to BTBD17
- Suitable for: WB, IHC-P
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-BTBD17 antibody [EPR9593(B)]
See all BTBD17 primary antibodies -
Description
Rabbit monoclonal [EPR9593(B)] to BTBD17 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-Pmore details
Unsuitable for: ICC/IF or IP -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide within Human BTBD17 aa 1-100. The exact sequence is proprietary.
-
Positive control
- Human colon cancer, Human fetal kidney, and Human bladder lysates, Human kidney clear cell carcinoma and Human liver tissues.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR9593(B) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab138507 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/10000. Predicted molecular weight: 52 kDa.
|
|
IHC-P |
1/50 - 1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
|
Notes |
---|
WB
1/1000 - 1/10000. Predicted molecular weight: 52 kDa. |
IHC-P
1/50 - 1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. |
Target
-
Sequence similarities
Contains 1 BACK (BTB/Kelch associated) domain.
Contains 1 BTB (POZ) domain. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 388419 Human
- SwissProt: A6NE02 Human
- Unigene: 211870 Human
-
Alternative names
- BTB (POZ) domain containing 17 antibody
- BTB/POZ domain-containing protein 17 antibody
- btbd17 antibody
see all
Images
-
All lanes : Anti-BTBD17 antibody [EPR9593(B)] (ab138507) at 1/1000 dilution
Lane 1 : Human colon cancer lysate
Lane 2 : Human fetal kidney tissue lysate
Lane 3 : Human bladder lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 52 kDa -
Immunohistochemical analysis of paraffin embedded Human kidney clear cell carcinoma tissue labelling BTBD17 with ab138507 antibody at a dilution of 1/50.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
-
Immunohistochemical analysis of paraffin embedded Human liver tissue labelling BTBD17 with ab138507 antibody at a dilution of 1/50.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (2)
ab138507 has been referenced in 2 publications.
- Shao H et al. Establishment and Verification of a Gene Signature for Diagnosing Type 2 Diabetics by WGCNA, LASSO Analysis, and In Vitro Experiments. Biomed Res Int 2022:4446342 (2022). PubMed: 35655479
- Kobayashi J et al. Extracellular a-synuclein enters dopaminergic cells by modulating flotillin-1-assisted dopamine transporter endocytosis. FASEB J 33:10240-10256 (2019). PubMed: 31211923